The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

TAK FINANCIAL STATEMENTS

Takeda Pharmaceutical Co Ltd ADR — balance sheet, income statement and cash flow trends

TAKTakeda Pharmaceutical Co Ltd ADR

🇺🇸 USA · US · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
02 T4 T202120222023202420252026

Profit Funnel

Q1 2026 · TTM
Revenue4.5 T ¥Gross Profit2.7 T ¥ · 58%Operating Income495.2 B ¥ · 11%Pre-tax Income261.6 B ¥ · 6%Net Income193.2 B ¥ · 4%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue4.5 T ¥-0.7%
Gross Profit2.7 T ¥-11.4%
Operating Income495.2 B ¥+44.5%
EBITDA1.4 T ¥+19.9%
Net Income193.2 B ¥+79.1%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
TAK-0.7%58.5%30.1%4.2%
Industry median7.5%60.6%18.2%4.0%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
05 T10 T15 T202120222023202420252026

Capital Structure

Q1 2026
Total Assets15.5 T
  • Equity7.8 T ¥50%
  • Current Liabilities2.4 T ¥16%
  • Long-term Liabilities5.3 T ¥34%

Key Figures

YoY change
Total Assets15.5 T ¥+8.9%
Total Liabilities7.7 T ¥+5.5%
Total Equity7.8 T ¥+12.6%
Cash & ST Investments597.6 B ¥+47.3%
Total Debt4.9 T ¥+8.6%
Net Debt4.3 T ¥+4.2%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
TAK1.2762.8%3.1450.3%
Industry median2.2246.3%1.2445.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
0500 B1 T202120222023202420252026

Cash Flow Bridge

Q1 2026 · TTM
0500 B1 T986.6 B ¥Operating-369.5 B ¥Investing-451.1 B ¥Financing166 B ¥Net Change

Key Figures

YoY change
Operating Cash Flow986.6 B ¥-6.7%
Capital Expenditures395.9 B ¥+86.4%
Free Cash Flow590.6 B ¥-30.1%
Dividends Paid-304.6 B ¥-200.7%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
TAK21.7%13.0%8.7%510.7%
Industry median15.2%11.6%2.5%84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on TAK

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. This content is for informational purposes only and is not investment advice.